---
document_datetime: 2023-09-21 20:15:39
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/tysabri-epar-procedural-steps-taken-authorisation_en.pdf
document_name: tysabri-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5294763
conversion_datetime: 2025-12-27 23:05:28.868861
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## 1 BACKGROUND INFORMATION ON THE PROCEDURE

## 1.1 Submission of the dossier

The applicant Elan Pharma International Ltd submitted on 3 June 2004 an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Tysabri,  through  the  centralised procedure.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application

## Scientific Advice:

The applicant received Scientific Advice from the CHMP on 17 October 2002. The Scientific Advice pertained to quality and clinical aspects of the dossier.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Dr Manfred Haase

Co-Rapporteur:

Dr P. Rossi

EMEA Product Team Leader: Dr Eric Pelfrene

## 1.2 Steps taken for the assessment of the product

- The application was received by the EMEA on 3 June 2004.
- The procedure started on 24 June 2004.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 30 August 2004 . The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 3 September 2004.
- During  the  meeting  on  18-21  October  2004,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  21 October 2004.
- During the meeting on 15-17 March 2005, the CHMP agreed on an Addendum to the CHMP Day 120 List of Questions to be sent to the applicant. The Addendum to the List of Questions was sent to the applicant on 18 March 2005.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 6 October 2005.
- â€¢
- The following inspections were carried out during the assessment of the application:
- Biogen Idec Inc - 14 Cambridge Center - Cambridge, MA - USA, on 5 - 7 January 2005, by the Dutch Competent Authorities, outcome of the inspection: positive; Biogen Idec Inc - One Antibody Way - Oceanside, CA - USA, on 3 January 2005, by the Dutch Competent Authorities, outcome of the inspection: positive; 19 -22 October 2004, by the Dutch Competent Authorities, outcome of the inspection: positive;
- Biogen U.S. Limited Partnership - 5000 Davis Drive, Research Triangle Park - NC - USA, on Sicor Pharmaceuticals Inc - 21 Hughes - Irvine, CA - USA, on 25-29 April 2005, by the UK Competent Authorities, outcome of the inspection: positive;
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 14 November.
- During a meeting of the Scientific Advisory Group (SAG) for CNS on 11 January 2006 experts were convened to address questions raised by the CHMP.
- During the CHMP meeting on 23-26 January 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.

.

<div style=\"page-break-after: always\"></div>

- The Rapporteurs circulated the Day 180 Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 31 March. On 19 April an amendment to the clinical Assessment Report was circulated with an updated respond to question 4.
- During  the  CHMP  meeting  on  24-27  April  2006,  outstanding  issues  were  addressed  by  the applicant during an oral explanation before the CHMP.
- During the meeting on  24-27 April 2006, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Tysabri  on  27  April  2006.  The  applicant  provided  the  letters  of undertaking on the follow-up measures to be fulfilled post-authorisation and on the proposed observational cohort study on 27 April 2006.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 27 June 2006.